Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Aptevo Therapeutics ( (APVO) ) has shared an announcement.
On July 24, 2025, Aptevo Therapeutics Inc. held its Annual Meeting of Stockholders where eight proposals were considered and voted upon. Key decisions included the election of directors, approval of a reverse stock split, and the issuance of stock under agreements with Yorkville, reflecting strategic moves to strengthen its financial position and governance structure.
The most recent analyst rating on (APVO) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aptevo Therapeutics stock, see the APVO Stock Forecast page.
Spark’s Take on APVO Stock
According to Spark, TipRanks’ AI Analyst, APVO is a Underperform.
Aptevo Therapeutics’ stock score is significantly impacted by its challenging financial performance, marked by declining revenues, high leverage, and negative cash flows. The technical analysis indicates bearish momentum, while the valuation is weakened by persistent losses. However, promising developments in its oncology pipeline offer potential upside if successfully executed.
To see Spark’s full report on APVO stock, click here.
More about Aptevo Therapeutics
Aptevo Therapeutics Inc. operates in the biotechnology industry, focusing on the development of novel immuno-oncology and hematology therapeutics. The company is known for its proprietary ADAPTIR platform, which is designed to generate bispecific antibodies for the treatment of cancer and other diseases.
Average Trading Volume: 2,356,163
Technical Sentiment Signal: Strong Sell
Current Market Cap: $10.45M
For a thorough assessment of APVO stock, go to TipRanks’ Stock Analysis page.